SUMMARY One hundred and five patients with rheumatoid arthritis treated with a variety of antirheumatic drugs, excepting glucocorticoids, were stratified according to the degree of functional impairment (functional classes I to IV) and duration of the disease (0-3 years; 4-8 years; and >8 years). The variables investigated were distal forearm bone mineral content (BMC), biochemical markers of bone formation: serum alkaline phosphatase and serum bone gamma-carboxyglutamic acid containing protein (BGP) and biochemical markers of bone resorption: fasting urinary calcium and fasting urinary hydroxyproline. Significant relationships were found between BMC and functional impairment and duration of the disease. Indices of bone formation and bone resorption rose with increasing functional impairment, particularly those of bone resorption. It is concluded that disability induces osteopenia in rheumatoid arthritis by increasing the bone turnover with a more marked increased in resorption than in the formation processes. The effect of the disease duration is merely that of adding more years of functional impairment.
Patients with rheumatoid arthritis (RA) have osteopenia -4 and a disturbance of the calcium metabolism. 5 The bone loss is pronounced in glucocorticoid treated patients' 3 4but is also present in patients treated solely with non-steroidal antirheumatic drugs.' 3 4 It has not been established whether RA-associated osteopenia, if uninfluenced by glucocorticoids, is determined by the degree of functional impairment (disability, impaired ambulation),6-9 or by the duration of the disease.' 9 10 Nor is it known whether the bone loss and the biochemical disturbances of calcium metabolism are proportional to these clinical variables.
In order to investigate these relationships we have evaluated the degree of functional impairment, measured the bone mineral content (BMC) in the distal forearms, and determined serum and urinary biochemical indices of the calcium metabolism in Accepted for publication 8 January 1985. Correspondence to Dr Orla S Als, Department 
Results
Patients in FC II and FC III + IV had a significantly longer duration of RA than patients in FC I (Table  2) . Correspondingly, patients with a duration of RA longer than eight years had a significantly lower functional ability (higher functional class) than the patients with a disease duration of 0-3 years (Table  3) . No significant age differences were found between different strata (Tables 2 and 3 ). Patients in FC II and FC III + IV had significantly lower BMC than patients in FC I, whereas no significant difference in BMC was found between FC II and FC III + IV (Fig. 1A) . Patients with a disease duration of four years or more had significantly lower BMC than those with a disease duration of less than four years (Fig. 1B) . The alkaline phosphatase was significantly higher in FC II and FC III + IV than in FC I, and also significantly higher in FC III + IV than in FC II (Fig. 2) . The level of serum alkaline phosphatase in patients with FC III + IV exceeded the upper limit of the normal reference interval for tDifference between functional classes I and Ill + IV (p<0-05). (Fig. 2) . No significant differences were found between the different functional classes with regard to fasting urinary calcium. Fasting urinary hydroxyproline was significantly higher in FC III + IV than in both FC I and FC II, but there was no difference between FC I and FC II (Fig. 2) . Serum calcium was significantly higher in FC III + IV than in FC I and serum phosphate was significantly higher in FC II than in FC I ( Table 2) . Patients with a disease duration of four years or more had significantly higher serum alkaline phosphatase than those with a duration of RA of less than four years (Fig. 3) . No significant differences were found between the three different groupings of disease duration (0-3 years, 4-8 years, and >8 years) with regard to serum BGP, fasting urinary calcium, fasting urinary hydroxyproline, serum calcium, and serum phosphate (Fig. 3 and disease duration of three years or less seems to imply a reduction in BMC from normal levels of less than 10%. If the functional impairment increases (FC II) or the disease has lasted four years or more the BMC will be as low as 85%. Progression from FC II to FC III or from less than eight to more than eight years of active RA does not seem to have any substantial influence on the BMC. It is therefore likely that the main part of the bone involvement takes place in the first three years of RA. The present data do not clarify which of the two, functional impairment or duration of RA, carries the principal load on the bone mass. However, since physical inactivity is a potent bone mass diminishing factor,2' it is probable that the influence of disease (Tables 2  and 3 ). This study agrees with a recent observation that disability and impaired ambulation are associated with an increased incidence of osteoporotic fractures in rheumatoid arthritis.22
Serum levels of alkaline phosphatase and BGP are biochemical markers of bone formation;2126
and fasting urinary calcium and fasting urinary hydroxyproline are markers of bone resorption.26
Together, an increase in these indices would imply an increased turnover of bone tissue.
Our findings (Fig. 2) suggest that increased bone turnover in patients with a high degree of functional impairment is the cause of the reduction in BMC.
The clearly raised levels of alkaline phosphatase with increasing functional impairment may be the liver fraction as well as the bone fraction,28 and the lack of a significant relationship between the functional class and the fasting urinary calcium may be due to h 'pocalcaemia as found in some rheumatic patients. Both fasting urinary hydroxyproline and serum BGP were significantly higher in FC III + IV as compared with FC I, but the greater difference from FC I to FC III + IV in fasting urinary hydroxyproline (approximately 40%) than in serum BGP (approximately 20%) suggests a preponderance of resorption over formation processes.
Stratification according to duration of the disease (Fig. 3) 
